Cargando…

A novel human induced pluripotent stem cell blood-brain barrier model: Applicability to study antibody-triggered receptor-mediated transcytosis

We have developed a renewable, scalable and transgene free human blood-brain barrier model, composed of brain endothelial cells (BECs), generated from human amniotic fluid derived induced pluripotent stem cells (AF-iPSC), which can also give rise to syngeneic neural cells of the neurovascular unit....

Descripción completa

Detalles Bibliográficos
Autores principales: Ribecco-Lutkiewicz, Maria, Sodja, Caroline, Haukenfrers, Julie, Haqqani, Arsalan S., Ly, Dao, Zachar, Peter, Baumann, Ewa, Ball, Marguerite, Huang, Jez, Rukhlova, Marina, Martina, Marzia, Liu, Qing, Stanimirovic, Danica, Jezierski, Anna, Bani-Yaghoub, Mahmud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789839/
https://www.ncbi.nlm.nih.gov/pubmed/29382846
http://dx.doi.org/10.1038/s41598-018-19522-8
Descripción
Sumario:We have developed a renewable, scalable and transgene free human blood-brain barrier model, composed of brain endothelial cells (BECs), generated from human amniotic fluid derived induced pluripotent stem cells (AF-iPSC), which can also give rise to syngeneic neural cells of the neurovascular unit. These AF-iPSC-derived BECs (i-BEC) exhibited high transendothelial electrical resistance (up to 1500 Ω cm(2)) inducible by astrocyte-derived molecular cues and retinoic acid treatment, polarized expression of functional efflux transporters and receptor mediated transcytosis triggered by antibodies against specific receptors. In vitro human BBB models enable pre-clinical screening of central nervous system (CNS)-targeting drugs and are of particular importance for assessing species-specific/selective transport mechanisms. This i-BEC human BBB model discriminates species-selective antibody- mediated transcytosis mechanisms, is predictive of in vivo CNS exposure of rodent cross-reactive antibodies and can be implemented into pre-clinical CNS drug discovery and development processes.